The Fourth Affiliated Hospital of Anhui Medical University
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tang, Min
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

Recruiting
2
108
RoW
Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group
Ganzhou Hemay Pharmaceutical Co., Ltd
Moderate to Severe Ulcerative Colitis
06/24
09/24
PSOT, NCT03481413: Patient Specific Optimized Therapy Post-Market Clinical Follow-up Study

Terminated
N/A
566
Europe, US, RoW
Ablation
EPD Solutions, A Philips Company
Arrythmia
03/23
03/23
NCT05731882: First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder

Recruiting
N/A
10
RoW
E-SeaLA, CardioPulse PFA system
Hangzhou Dinova EP Technology Co., Ltd
Nonvalvular Atrial Fibrillation
06/24
08/24
Xia, Yunhong
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
3
332
RoW
TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer
07/22
07/22
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting
2
42
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
06/26
06/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tang, Min
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

Recruiting
2
108
RoW
Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group
Ganzhou Hemay Pharmaceutical Co., Ltd
Moderate to Severe Ulcerative Colitis
06/24
09/24
PSOT, NCT03481413: Patient Specific Optimized Therapy Post-Market Clinical Follow-up Study

Terminated
N/A
566
Europe, US, RoW
Ablation
EPD Solutions, A Philips Company
Arrythmia
03/23
03/23
NCT05731882: First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder

Recruiting
N/A
10
RoW
E-SeaLA, CardioPulse PFA system
Hangzhou Dinova EP Technology Co., Ltd
Nonvalvular Atrial Fibrillation
06/24
08/24
Xia, Yunhong
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
3
332
RoW
TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer
07/22
07/22
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting
2
42
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
06/26
06/28

Download Options